



MedStar Family Choice

ADMINISTRATIVE POLICY AND PROCEDURE

Policy #:	1427	
Subject:	Non-Invasive Prenatal Aneuploidy and Other Prenatal Genetic Testing	
Section:	Medical Non-Pharmacy Protocols	
Initial Effective Date:	12/03/2020	
Revision Effective Date(s):	07/21, 07/22, 07/23, 07/24	
Review Effective Date(s):	7/25	
Responsible Parties:	Medical Director	
Responsible Department(s):	Clinical Operations	
Regulatory References:	MDH Policy Non-Invasive Prenatal Testing (NIPTs) Clinical Criteria (12/20/20) and Non-Invasive Prenatal Testing (NIPTs) Ordering Guidelines; MDH Whole Exome Sequencing (WES) Clinical Criteria	
Approved:	AVP Clinical Operations	Chief Medical Officer

Purpose: To define the conditions under which MedStar Family Choice (MFC) will provide Non-Invasive Prenatal Aneuploidy Testing and other prenatal genetic testing for screening.

Scope: MedStar Family Choice, Maryland

Policy: It is the policy of MFC to offer non-invasive prenatal screening testing without authorization for trisomy 13, 18 and 21 in accordance with MDH and ACOG recommendations. Testing beyond these screening tests will require prior authorization.

Procedure:

Basic Screening:

1. Prenatal screening for fetal aneuploidy will be available for all pregnant women without prior authorization starting at 10 weeks gestational age for **singleton pregnancy only**.
2. First Trimester Screening should include an ultrasound and aneuploidy screening OR traditional Quad screening but NOT both. Ultrasound with NIPTs is the preferred method.
3. LabCorp and Myriad are MedStar Family Choice's contracted laboratories. OB GYN providers must send samples to one of these laboratories.

4. For LabCorp, the **only** test ordered should be “**MaterniT21 PLUS Core + SCA**”. It is **LabCorp test #451934** and it will report aneuploidy for chromosome 21, 18 and 13, sex chromosome aneuploidy (Turner syndrome, Klinefelter syndrome, etc.) and sex of the baby. If this **EXACT** test is ordered, no prior authorization will be required. Any other test will require prior authorization.
5. For Myriad, on their order form under *Myriad Prequel Prenatal Screen -Noninvasive prenatal screen*, check the box for *Common aneuploidy, chromosome 13, 18, 21 AND* check the box next to *Include sex chromosome analysis*. If these two boxes are checked, no prior authorization will be required. Any other test will require prior authorization. (see Myriad Order Form inserted below)
6. Second Trimester Screening should still include a detailed anatomic ultrasound and an alfa fetal protein level.

Advanced Testing:

Further genetic testing will require prior authorization and must be ordered by a Maternal Fetal Medicine Specialist or after consultation with a Genetic Counselor. Further testing will be considered when fetal ultrasound findings show anatomic abnormalities.

1. Requests must be submitted with evidence of consultation with a Maternal Fetal Medicine Specialist or a Genetic Counselor.
2. The medical records submitted must indicate the reason for the request, the condition suspected and the anticipated actions or change of clinical management to be taken based on the outcome of the testing.
3. For LabCorp, the specific testing requested would be **MaterniT21 Genome Add On (LabCorp test # 452104 or 452114** if redraw needed) which would return a “comprehensive chromosome copy number analysis including unbalanced derivatives, and information about deletions or duplications of chromosome material 7 Mb or larger, as well as analysis of seven clinically relevant microdeletions less than 7 Mb in size.” Any other version of the LabCorp MaterniT21 tests would duplicate the original screening test and is thus not medically necessary.
4. For Myriad, on their order form check **ONLY** the box next to *microdeletions, singleton only* (see Myriad Order Form inserted below)
5. Any other genetic testing will require consultation with Maternal Fetal Medicine or Genetic Counselor and documentation as in 2. above.

Excluded From Coverage:

Per MDH NIPTs Clinical Criteria document the following are excluded from coverage:

1. Testing as a follow-up to an abnormal 1st or 2nd trimester screening
2. Low Fetal Fraction on initial NIPTs testing (counseling and diagnostic testing recommended)
3. Cases with a known co-twin demise (vanishing twin syndrome)
4. Screening for trisomies other than 21, 18, and 13
5. Screening for single-gene disorders
6. Whole genome NIPTs
7. Whole exome sequencing

8. When used to determine genetic cause of miscarriage or fetal demise (e.g., missed abortion, incomplete abortion)

Out of Network Testing:

1. All requests for out of network laboratories will require prior authorization and will only be approved if the testing is not available from an in-network laboratory and is determined to be medically necessary.

Per the MDH policy

CPT 81420 (Fetal chromosomal aneuploidy (e.g., trisomy **21**, monosomy X) genomic sequence analysis panel, circulating cell- free fetal DNA in maternal blood, must include analysis of chromosomes **13**, **18**, and **21**) - no PA for Prenatal testing

CPT 81507 (Fetal aneuploidy (trisomy **21**, **18**, and **13**) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy) - no PA for Prenatal testing

CPT 81422 (Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood) - PA required

CPT 81479 (Unlisted molecular pathology procedure)– PA required (this CPT may only be used for NIPTs testing)

References: Content created in conjunction with MSH OBGYN Clinical Practice Council.

Attachments:

Attachment A – Myriad Order Form

Summary of Changes:	7/25 • No changes 07/24: • Removed specific names for “Responsible Parties” and “Approved”; just using titles • Added WES exclusion as per MDH WES Clinical Criteria 07/23: • Updated approved by to Carol Attia and Dr. Wills • Clarified when advanced testing will be considered • Added exclusions as per MDH 07/22: • Added Attachment A - Myriad Order Form. 07/21: • Updated Responsible Departments from Utilization Management to Clinical Operations. 12/20: • New policy.
----------------------------	--

